Information  X 
Enter a valid email address

Benchmark Hlgs PLC (BMK)


Monday 18 October, 2021

Benchmark Hlgs PLC

Trading Statement

RNS Number : 3051P
Benchmark Holdings PLC
18 October 2021

18 October 2021


Information within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulations (EU) No. 596/2014.

Benchmark Holdings plc

("Benchmark", the "Company" or the "Group")


Trading Update and Notice of Results


FY21 Results expected to be significantly ahead of market expectations

Continued good momentum across all business areas



Benchmark, the aquaculture biotechnology business, is pleased to provide an update ahead of its full year results for the year ended 30 September 2021, which will be announced on 29th November 2021.


Following positive financial results in Q3 2021, the Company maintained this momentum in Q4 2021 and has delivered a stronger than expected trading performance across its three business areas driven by the Group's continued strong commercial focus, disciplined cost control and further recovery in the Company's end markets. The Group's Advanced Nutrition business area has continued to deliver excellent year on year growth while the Group's Genetics business area delivered a strong end to the year, and in the Group's Health business area, the Company achieved its first revenues from its sea lice treatment, Ectosan ® Vet and CleanTreat ®; all business areas delivered above the Board's expectations in September.


As a result, whilst still subject to audit, the Group's Adjusted EBITDA for FY21 is expected to be significantly ahead of the current market consensus which is £15.9m.

Trond Williksen, CEO, commented:


"We are pleased by the continuing momentum in the business, which reflects the benefits of our clear commercial focus, having streamlined the organisation, our continued disciplined approach to cost control and good demand for our products in our recovering markets.


"As a focused aquaculture biotechnology company with three strong business areas, we are well positioned to capture market opportunities and deliver profitable growth."



Notice of Results and details of analyst / investor call


The Company will announce its full year results on 29 November 2021. Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial Officer will host a webcast for analysts and institutional investors on that day at 8:30am UK time. To register your interest, please contact  [email protected] .




For further information, please contact:


Benchmark Holdings plc

Tel:  020 3696 0630

Trond Williksen, CEO


Septima Maguire, CFO


Ivonne Cantu, Investor Relations






Numis (Broker and NOMAD)

Tel:  020 7260 1000

James Black, Freddie Barnfield, Duncan Monteith





MHP Communications

Tel:  020 3128 8990 / 8742

Katie Hunt, Reg Hoare, Alistair de Kare-Silver      [email protected]



About Benchmark 

Benchmark is a leading aquaculture biotechnology company. Benchmark's mission is to enable aquaculture producers to improve their sustainability and profitability.

We bring together biology and technology to develop innovative products and solutions which improve yield, quality and animal health and welfare for our customers. We do this by improving the genetic make-up, health and nutrition of their stock - from broodstock and hatchery through to nursery and grow out.

Benchmark has a broad portfolio of products and solutions, including salmon eggs, live feed (Artemia), specialist diets and probiotics and sea lice treatments. Find out more at


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t